11,397 Shares in CARGO Therapeutics, Inc. (NASDAQ:CRGX) Bought by XTX Topco Ltd

XTX Topco Ltd purchased a new stake in CARGO Therapeutics, Inc. (NASDAQ:CRGX) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 11,397 shares of the company’s stock, valued at approximately $46,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Corton Capital Inc. purchased a new position in CARGO Therapeutics during the first quarter worth about $113,000. Peapod Lane Capital LLC acquired a new position in CARGO Therapeutics in the 1st quarter valued at $892,000. Bank of New York Mellon Corp raised its holdings in CARGO Therapeutics by 7.8% in the 1st quarter. Bank of New York Mellon Corp now owns 95,529 shares of the company’s stock valued at $389,000 after acquiring an additional 6,893 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of CARGO Therapeutics by 7.2% in the 4th quarter. Wellington Management Group LLP now owns 2,190,811 shares of the company’s stock valued at $31,591,000 after purchasing an additional 148,088 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of CARGO Therapeutics by 31.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,832 shares of the company’s stock valued at $214,000 after purchasing an additional 3,570 shares during the last quarter. 93.16% of the stock is owned by hedge funds and other institutional investors.

CARGO Therapeutics Stock Performance

NASDAQ CRGX opened at $4.54 on Friday. The company has a 50-day simple moving average of $4.45 and a 200-day simple moving average of $4.20. The firm has a market capitalization of $219.55 million, a PE ratio of -0.98 and a beta of 0.30. CARGO Therapeutics, Inc. has a one year low of $3.00 and a one year high of $25.45.

Analysts Set New Price Targets

Separately, Jefferies Financial Group lifted their price target on shares of CARGO Therapeutics from $3.70 to $5.00 and gave the stock a “hold” rating in a research note on Tuesday, July 8th. One investment analyst has rated the stock with a sell rating and six have assigned a hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $15.40.

About CARGO Therapeutics

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.